Rosetta and Moffitt Partner to Develop microRNA Cancer Diagnostic
|
By LabMedica International staff writers Posted on 16 Jun 2014 |
|
Rosetta Genomics, Ltd. (Princeton, NJ, USA; Rehovot, Israel), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, has entered into an agreement with Moffitt Cancer Center (Tampa, FL, USA) to advance the development and commercialization of Rosetta's thyroid neoplasia assay. Rosetta will work with Marino Leon, MD, associate member of the department of anatomic pathology at Moffitt.
Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”
Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”
Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.
Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.
Related Links:
Rosetta Genomics
Moffitt Cancer Center
Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”
Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”
Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.
Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.
Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.
Related Links:
Rosetta Genomics
Moffitt Cancer Center
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Latest Industry News
- Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval
- Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
- Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
- New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing
- Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing
- Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
- Sputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
- Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
- Unilabs Expands Digital Pathology Across European Network with Proscia Platform
- Digital Pathology Partnership Integrates Breast Cancer Diagnostic and Prognostic Tools
- MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
- Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
- Sepsis Diagnostics Market Growth Fueled by Faster Pathogen Detection Needs
- Project Advances Single-Cell Diagnostic Test for Triple-Negative Breast Cancer
- Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry
- Health Canada Licenses Point-of-Care Hematology Analyzer for Decentralized CBC Testing
Channels
Clinical Chemistry
view channel
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Global Survey Underscores Need to Standardize Bone Biomarker Testing
Bone and mineral metabolism biomarkers can complement dual-energy X-ray absorptiometry (DXA) by providing information on disease activity and treatment response. For more than 20 years, standardization... Read more
Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more
Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
Blood clots can rapidly become life‑threatening and affect approximately 10 million people worldwide each year. During time‑sensitive evaluations, clinicians use D‑dimer testing to help rule out deep vein... Read moreMolecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more
Microbiology
view channel
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
